Novozymes A/S (NVZMY) Stock Price, News & Analysis

Company Overview

Novozymes A/S is a global biotechnology company headquartered in Bagsværd, Denmark, specializing in the research, development and production of industrial enzymes and microorganisms. Since its spin-off from Novo Nordisk in 2000, Novozymes has become a leading supplier of biological solutions designed to enhance process efficiency, sustainability and resource utilization across a wide range of industries.

The company’s core offerings include enzyme formulations for applications in agriculture, bioenergy, food and beverages, household care, textile processing, pulp and paper, animal feed and waste treatment. By tailoring its biocatalysts to customer needs, Novozymes helps manufacturers lower energy and water consumption, reduce chemical usage and improve product quality. Key product lines include feed enzymes that support animal nutrition, cellulases for bioethanol production and amylases for starch conversion in food processing.

Novozymes serves customers in more than 100 countries, operating production facilities and application centers in Europe, North America, South America and Asia-Pacific. The company’s global footprint supports close collaboration with multinational corporations and local enterprises alike, enabling rapid adoption of enzyme technologies. Under the leadership of CEO Ester Baiget, who took the helm in 2021, Novozymes has continued to expand its market presence in emerging economies such as China, Brazil and India.

Research and development remain central to Novozymes’ strategy, with a workforce of scientists and engineers dedicated to discovering new biological solutions. The company invests heavily in sustainability initiatives, leveraging its expertise in fermentation and microbial engineering to develop climate-friendly processes. Through partnerships with industry, academia and public institutions, Novozymes aims to foster innovation that addresses global challenges such as food security, renewable energy and environmental protection.

Key Stats

• Today's Range: $69.58 to $70.43
• 50-Day Range: $65.28 to $75.47
• 52-Week Range: $53.95 to $75.99
• Volume: 11,955 shs
• Average Volume: 54,592 shs
• Market Capitalization: $32.75 billion
• P/E Ratio: 44.26
• Dividend Yield: 1.09%
• Price Target: N/A
• Consensus Rating: Buy

Novozymes A/S Stock Analysis - MarketRank™

Novozymes A/S scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Novozymes A/S.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 17.58%

Earnings Growth

Earnings for Novozymes A/S are expected to grow by 17.58% in the coming year, from $1.82 to $2.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novozymes A/S is 44.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.98.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novozymes A/S is 44.26, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 101.44.

Price to Earnings Growth Ratio

Novozymes A/S has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novozymes A/S has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Novozymes A/S has been sold short.

Short Interest Ratio / Days to Cover

Novozymes A/S has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novozymes A/S has recently increased by 179.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novozymes A/S pays a meaningful dividend of 1.08%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novozymes A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novozymes A/S is 48.10%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 35.51% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Novozymes A/S has been sold short.

Short Interest Ratio / Days to Cover

Novozymes A/S has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novozymes A/S has recently increased by 179.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Novozymes A/S has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Basic Materials companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Novozymes A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novozymes A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.03% of the stock of Novozymes A/S is held by institutions.

NVZMY Stock Analysis - Frequently Asked Questions

How have NVZMY shares performed this year?

Novozymes A/S's stock was trading at $56.5399 on January 1st, 2025. Since then, NVZMY stock has increased by 23.7% and is now trading at $69.9250.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) announced its quarterly earnings results on Wednesday, January, 31st. The biotechnology company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.11. The biotechnology company earned $664.46 million during the quarter.

Does Novozymes A/S have any subsidiaries?

The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and others.

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 1/31/2024
• Record date for 4/23 Dividend: 4/07/2025
• Ex-Dividend for 4/23 Dividend: 4/07/2025
• Dividend Payable: 4/23/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Basic Materials
• Industry: CHEM - SPECIALTY
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NVZMY
• Previous Symbol: OTC:NVZMY
• CIK: 1131345
• Web: www.novozymes.com
• Phone: (454) 446-0000
• Fax: 45-4446-9999
• Employees: 10,582
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 44.21
• Forward P/E Ratio: 38.38
• P/E Growth: 1.33
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 1.66
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $4.15 billion
• Price / Sales: 7.88
• Cash Flow: $1.85 per share
• Price / Cash Flow: 37.70
• Book Value: $25.82 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 468,300,000
• Free Float: N/A
• Market Cap: $32.71 billion
• Optionable: Not Optionable
• Beta: 0.91